mTOR pathway: A current, up-to-date mini-review

94Citations
Citations of this article
250Readers
Mendeley users who have this article in their library.

Abstract

Mammalian target of rapamycin (mTOR) is a protein serine/threonine kinase that was initially identified as the cellular target of rapamycin. This kinase regulates cell growth, proliferation, motility and survival, as well as the gene transcription and protein synthesis that are activated in response to hormones, growth factors and nutrients. Results from preclinical studies have indicated that factors antagonizing the mTOR pathway exert an antitumor effect on lung cancer. Furthermore, primary clinical trials of mTOR inhibitors have demonstrated that the inhibitors may be effective against lung carcinoma. The present study explores the association between mTOR and lung carcinogenesis and describes the clinical trials of mTOR inhibitors.

Author supplied keywords

Cite

CITATION STYLE

APA

Zarogoulidis, P., Lampaki, S., Francis Turner, J., Huang, H., Kakolyris, S., Syrigos, K., & Zarogoulidis, K. (2014, December 1). mTOR pathway: A current, up-to-date mini-review. Oncology Letters. Spandidos Publications. https://doi.org/10.3892/ol.2014.2608

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free